Related Experiment Video
Updated: Sep 18, 2025

09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.3K
Prediction of Alzheimer's Disease Based on Multi-Modal Domain Adaptation
Binbin Fu1,2, Changsong Shen1,2, Shuzu Liao3
1School of Mathematics and Statistics, Hainan Normal University, Haikou 571158, China.
Brain Sciences
|June 26, 2025
Summary
This study introduces a novel multi-modal deep domain adaptation (MM-DDA) model for Alzheimer's disease (AD) classification, effectively integrating MRI and PET data to improve diagnostic accuracy.
Area of Science:
- Neuroimaging
- Artificial Intelligence
- Medical Diagnostics
Background:
- Alzheimer's disease (AD) diagnosis benefits from structural MRI and functional PET scans.
- Challenges include differing data structures and domain shift across datasets.
- Existing methods often overlook multi-modal complementarity and domain differences.
Purpose of the Study:
- To propose a Multi-modal Deep Domain Adaptation (MM-DDA) model for enhanced AD classification.
- To leverage complementary information from MRI and PET data.
- To mitigate domain distribution differences between datasets.
Main Methods:
- Developed an MM-DDA model integrating MRI and PET data.
- Employed CNNs for feature encoding, multi-head attention for feature fusion, and adversarial learning for domain transfer.
- Utilized data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset.
Main Results:
- Achieved high classification accuracies in transfer learning settings (e.g., ADNI1→ADNI2 and ADNI2→ADNI1).
- Accuracies for AD vs. CN reached up to 94.73%, and for pMCI vs. sMCI up to 81.81%.
- Demonstrated robust performance across various diagnostic comparisons.
Conclusions:
- The proposed MM-DDA model shows superior performance in AD prediction tasks.
- Effective integration of multi-modal data and domain adaptation significantly boosts classification accuracy.
- MM-DDA outperforms existing deep learning methods in transfer learning scenarios.
Related Concept Videos
Alzheimer's Disease: Overview
684
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
684
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Dementia
182
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
182

